TrialCancer science2010

Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.

Ken Ohmachi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.